Association between the BRCA2 rs144848 polymorphism and cancer susceptibility: a meta-analysis

Qiuyan Li, Rongwei Guan, Yuandong Qiao, Chang Liu, Ning He, Xuelong Zhang, Xueyuan Jia, Haiming Sun, Jingcui Yu and Lidan Xu _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:39818-39832. https://doi.org/10.18632/oncotarget.16242

Metrics: PDF 1623 views  |   HTML 1547 views  |   ?  


Qiuyan Li1,*, Rongwei Guan1,*, Yuandong Qiao1, Chang Liu1, Ning He2, Xuelong Zhang1, Xueyuan Jia1, Haiming Sun1, Jingcui Yu3 and Lidan Xu1

1 Laboratory of Medical Genetics, Harbin Medical University, Harbin, People’s Republic of China

2 Department of Clinical Laboratory, Qiqihar Traditional Chinese Medicine Hospital, Qiqihar, People’s Republic of China

3 The Second Affiliated Hospital, Harbin Medical University, Harbin, People’s Republic of China

* These authors have contributed equally to this work

Correspondence to:

Lidan Xu, email:

Jingcui Yu, email:

Keywords: meta-analysis; BRCA2; cancer; polymorphism; susceptibility

Received: August 26, 2016 Accepted: February 06, 2017 Published: March 15, 2017


The BRCA2 gene plays an important role in cancer carcinogenesis, and polymorphisms in this gene have been associated with cancer risk. The BRCA2 rs144848 polymorphism has been associated with several cancers, but results have been inconsistent. In the present study, a meta-analysis was performed to assess the association between the rs144848 polymorphism and cancer risk. Literature was searched from the databases of PubMed, Embase and Google Scholar before April 2016. The fixed or random effects model was used to calculate pooled odd ratios on the basis of heterogeneity. Meta-regression, sensitivity analysis, subgroup analysis and publication bias assessment were also performed using STATA 11.0 software according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2009. A total of 40 relevant studies from 30 publications including 34,911 cases and 48,329 controls were included in the final meta-analysis. Among them, 22 studies focused on breast cancer, seven on ovarian cancer, five on non-Hodgkin lymphoma, and the remaining six studies examined various other cancers. The meta-analysis results showed that there were significant associations between the rs144848 polymorphism and cancer risk in all genetic models. Stratified by cancer type, the rs144848 polymorphism was associated with non-Hodgkin lymphoma. Stratified by study design, the allele model was associated with breast cancer risk in population-based studies. The meta-analysis suggests that the BRCA2 rs144848 polymorphism may play a role in cancer risk. Further well-designed studies are warranted to confirm these results.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 16242